Immunovant, Inc. announced that it has signed a purchase agreement with existing investor Roivant Sciences Ltd. to issue 17,021,276 shares at a price of $11.75 per share for the gross proceeds for $199,999,993 on August 2, 2021. The investor stake has increased from 57.5% to 63.8% stake in the company. The issuance and sale of the Shares is exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.88 USD | -0.18% | +5.02% | -3.12% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.12% | 8.78B | |
+24.17% | 562B | |
-6.33% | 358B | |
+19.90% | 322B | |
+7.95% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-12.26% | 149B | |
-6.47% | 146B |
- Stock Market
- Equities
- ROIV Stock
- News Roivant Sciences Ltd.
- Immunovant, Inc. announced that it has received $199.999993 million in funding from Roivant Sciences Ltd.